

August 17, 2021

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Ms. Margaret Schwartz

**Re: Aptevo Therapeutics Inc.  
Registration Statement on Form S-3  
File No. 333-258758**

Dear Ms. Schwartz:

In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-258758) of Aptevo Therapeutics Inc. (the "Registration Statement"). We respectfully request that the Registration Statement become effective as of 4:05 p.m., Eastern Time, on August 19, 2021 or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Goodwin Procter LLP, by calling Sean M. Donahue at (202) 538-3557.

Very truly yours,

Aptevo Therapeutics Inc.

By: /s/ Marvin L. White  
Marvin L. White  
President and Chief Executive Officer

CC: SoYoung Kwon, Aptevo Therapeutics Inc.  
Daphne Taylor, Aptevo Therapeutics Inc.  
Sean M. Donahue, Goodwin Procter LLP